Welsing Paco M J, Bijl Marc, van Bodegraven Ad A, Lems Willem F, Prens Erol, Bijlsma J W J Hans
Universitair Medisch Centrum Utrecht, afd. Reumatologie & Klinische immunologie, Utrecht, the Netherlands.
Ned Tijdschr Geneeskd. 2011;155(29):A3026.
Where health care is concerned, the introduction of biologicals has greatly improved the treatment of chronic inflammatory disorders. This class of drugs is not only noticeably effective, but is also well tolerated. The cost effectiveness of these drugs means that there are limits to their use. This is the other face of success. The Dutch Ministry of Health, Welfare and Sport recently announced measures intended to limit the growth of costs while at the same time requiring that savings should be made on the current budget. Recently the Canadian Agency for Drugs and Technologies in Health (CADTH) produced a report on the effects and costs of biologicals for adults with rheumatoid arthritis (www.cadth.ca). Here we discuss their findings. Organizations for medical specialists should be societal aware and be able to deal with these drugs in a cost-conscious manner, including the development of dynamic guidelines and quality visitations.
在医疗保健领域，生物制剂的引入极大地改善了慢性炎症性疾病的治疗。这类药物不仅疗效显著，而且耐受性良好。这些药物的成本效益意味着其使用存在限制。这是成功的另一面。荷兰卫生、福利和体育部最近宣布了旨在限制成本增长的措施，同时要求在当前预算上实现节约。最近，加拿大卫生药品和技术局（CADTH）发布了一份关于生物制剂对类风湿性关节炎成年患者的疗效和成本的报告（www.cadth.ca）。在此我们讨论他们的研究结果。医学专家组织应该具有社会意识，并能够以注重成本的方式处理这些药物，包括制定动态指南和进行质量巡查。
